Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
about
Kynurenines in CNS disease: regulation by inflammatory cytokinesChronic Glutamate Toxicity in Neurodegenerative Diseases-What is the Evidence?Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's DiseaseKynurenine 3-Monooxygenase: An Influential Mediator of NeuropathologyKynurenines in the mammalian brain: when physiology meets pathologyMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.A genome-scale RNA-interference screen identifies RRAS signaling as a pathologic feature of Huntington's diseaseTryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolitesTargeted Deletion of Kynurenine 3-Monooxygenase in Mice: A NEW TOOL FOR STUDYING KYNURENINE PATHWAY METABOLISM IN PERIPHERY AND BRAINExpression analysis of novel striatal-enriched genes in Huntington disease.Mechanisms of copper ion mediated Huntington's disease progressionQuinolinic acid induced neurodegeneration in the striatum: a combined in vivo and in vitro analysis of receptor changes and microglia activation.Kynurenine Pathway Activation in Human African TrypanosomiasisMicroglial Activation in the Pathogenesis of Huntington's Disease.Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-D-aspartate neurotoxicity.Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo.Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration.The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1.High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes.Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder.Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of diseaseThe kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease.Dopamine and glutamate in Huntington's disease: A balancing act.Molecular mechanisms and potential therapeutical targets in Huntington's disease.Involvement of kynurenines in Huntington's disease and stroke-induced brain damage.The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease.Quinolinic acid: an endogenous neurotoxin with multiple targets.Major developments in the design of inhibitors along the kynurenine pathway.Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies.Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO).Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease.Migration of neurotrophic factors-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imaging.Decreasing Levels of the cdk5 Activators, p25 and p35, Reduces Excitotoxicity in Striatal Neurons.Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice.Inhibition of the kynurenine-NAD+ pathway leads to energy failure and exacerbates apoptosis in pneumococcal meningitis.Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment.Absence of aryl hydrocarbon receptors increases endogenous kynurenic acid levels and protects mouse brain against excitotoxic insult and oxidative stress.Rare Disease Mechanisms Identified by Genealogical Proteomics of Copper Homeostasis Mutant Pedigrees.
P2860
Q21129356-3C365557-0596-4C6B-9F6A-83BCF814E42AQ26770781-0E163257-90AF-4E70-880F-9FF5284E3DA6Q26781849-F708C964-14A1-40D6-AAC4-334FC57504A2Q26782867-9A9052D9-2B1D-40BA-AE7C-198108D7D21EQ27003296-126B24A6-CD66-4D15-A41C-BCA373715145Q27005950-4C25CA3C-A723-48A0-933F-26F5F0688D56Q28485362-8FBD5876-5239-43E5-B467-46C7A832B6A0Q28834131-A1285656-697D-402A-99EF-F11848761F89Q29306917-660C84C3-A8BB-4AD3-85FF-F0FA19508F41Q30476999-DDB0973A-D5FB-4CA4-A446-D90A73892A72Q33280572-9F345BE5-71A4-4F23-8EEB-2DA497DF2CEDQ33310422-83D759D8-7F31-49F0-B769-F2E8B162006CQ33553777-45A26C1E-6333-46CE-837D-11030FE4093CQ33809556-138B3348-355D-4CA5-8B72-43A1063517CDQ34654483-9BBF0CCA-0D31-4FC4-85B4-B1B0438117B9Q34780443-5BE4CC98-77EE-46DA-9BFB-9336C7A64303Q35054916-3B7491F6-2D0D-4F09-B12F-A782B16E2782Q35168004-E69CA08B-28E7-453A-BE35-06D5CFAD3B3DQ35175306-FF71CDFE-5B91-42BE-87FD-B83878149E9EQ35366778-FC2318DA-CD0D-4A56-8532-0D86242193C9Q37040974-31078B9A-CB9C-475F-BE3E-91C83676A301Q37311202-47FDCA9C-7D80-4EC5-91CF-6EA342166B96Q37318862-F0910204-F828-4D11-9F6A-888056A0BE7EQ37460122-058C1307-0D37-441E-84C7-AFCD61037FEDQ37734563-E5C5AEE8-3FDF-4C23-92D5-985FFCB6B395Q37776087-102DB421-6AB8-45D0-AB19-EB7AF8A9AB3EQ37892975-632E5060-3285-4157-8071-5AD54A60FC5FQ38103448-44CCAF70-FECF-4785-B833-EE6EFDA96134Q38148752-4603C2C1-6667-4C39-91CA-65E8C55E1BDBQ38808400-20179B45-1C94-4FB7-A8B9-DBD075544F02Q39035495-AF7C64E7-3729-40B5-9E11-308441FDD0E6Q39149450-4D2BFAA5-6B9F-4A86-A5A3-0BAE9C767F3CQ39399401-F9113317-5016-4809-A54F-34A37DC8C531Q40069509-7822AE96-1A4E-42F7-8700-1E45FED912A8Q42108493-2586487F-F1B0-4180-9709-720335333F6DQ42495952-A2B83B06-1490-43A1-B81A-7DE9BDCC3E4CQ42860959-6486BBC1-A769-4DCC-BE13-2153F7BFB6ACQ45307207-AE7C8C10-73D7-4DA1-9FBA-6B9C8BB1388DQ48158678-8CC48E70-C2D0-4A31-9182-EF730746EA31Q48514121-B48D8A72-BFF6-4BE5-8CE4-E3E22D078A9E
P2860
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
description
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2006
@ast
im Mai 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2006/07/01)
@sk
vědecký článek publikovaný v roce 2006
@cs
wetenschappelijk artikel (gepubliceerd op 2006/07/01)
@nl
наукова стаття, опублікована в липні 2006
@uk
مقالة علمية نشرت في يوليو 2006 حول موضوع: دماغ
@ar
name
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
@ast
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
@en
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
@nl
type
label
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
@ast
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
@en
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
@nl
prefLabel
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
@ast
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
@en
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
@nl
P2093
P50
P921
P1476
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
@en
P2093
Ben Woodman
Elizabeth J Slow
Paolo Guidetti
Robert Schwarcz
Rona K Graham
Vanessa C Wheeler
P304
P356
10.1016/J.NBD.2006.02.011
P577
2006-05-12T00:00:00Z